SynapDx Licenses Gene Expression Technology from Children's Hospital Boston | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup SynapDx said today it has licensed technology from Children's Hospital Boston for the development of blood-based tests for the early detection of autism spectrum disorders.

Citing statistics from the Centers for Disease Control, SynapDx said about one in every 110 children in the US has the disorder.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.